- Home
- SGC vs MNPR Comparison
SGC vs MNPR Comparison
Compare SGC & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGC
- MNPR
- Stock Information
- Founded
- SGC 1920
- MNPR 2014
- Country
- SGC United States
- MNPR United States
- Employees
- SGC N/A
- MNPR N/A
- Industry
- SGC Apparel
- MNPR Biotechnology: Pharmaceutical Preparations
- Sector
- SGC Consumer Discretionary
- MNPR Health Care
- Exchange
- SGC Nasdaq
- MNPR Nasdaq
- Market Cap
- SGC 215.7M
- MNPR 248.8M
- IPO Year
- SGC N/A
- MNPR 2019
- Fundamental
- Price
- SGC $11.79
- MNPR $49.22
- Analyst Decision
- SGC Strong Buy
- MNPR Strong Buy
- Analyst Count
- SGC 3
- MNPR 11
- Target Price
- SGC $17.33
- MNPR $68.60
- AVG Volume (30 Days)
- SGC 42.0K
- MNPR 39.3K
- Earning Date
- SGC 11-05-2025
- MNPR 11-07-2025
- Dividend Yield
- SGC 4.74%
- MNPR N/A
- EPS Growth
- SGC N/A
- MNPR N/A
- EPS
- SGC 0.52
- MNPR N/A
- Revenue
- SGC $576,240,000.00
- MNPR N/A
- Revenue This Year
- SGC $1.46
- MNPR N/A
- Revenue Next Year
- SGC $3.32
- MNPR N/A
- P/E Ratio
- SGC $22.63
- MNPR N/A
- Revenue Growth
- SGC 4.03
- MNPR N/A
- 52 Week Low
- SGC $9.11
- MNPR $2.40
- 52 Week High
- SGC $18.48
- MNPR $54.30
- Technical
- Relative Strength Index (RSI)
- SGC 46.13
- MNPR 67.11
- Support Level
- SGC $11.60
- MNPR $42.51
- Resistance Level
- SGC $12.27
- MNPR $45.78
- Average True Range (ATR)
- SGC 0.45
- MNPR 3.42
- MACD
- SGC -0.19
- MNPR 1.71
- Stochastic Oscillator
- SGC 8.72
- MNPR 97.14
About SGC Superior Group of Companies Inc.
Superior Group Of Companies Inc designs apparel products. The company's operating segment includes Branded Products; Healthcare Apparel and Contact Centers. It generates maximum revenue from the Branded Products segment. The Branded Products segment produce and sell customized merchandising solutions, promotional products and branded uniform programs to customers.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.